Potassium Citrate Tablet, Extended Release
Product Images NDC 72865-192

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Potassium Citrate (NDC 72865-192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

10meq

10meq
XLcare Pharmaceuticals Inc. sells Potassium Citrate Extended-Release Tablets, USP, containing 10 mEq (1080 mg) per tablet. The tablets are uncoated, capsule shaped, and off-white to tan yellowish in color. Each tablet is debossed with ‘T400 on one side and plain on the other side. The tablets are supplied in a container with a child-resistant closure. The recommended storage temperature for the tablets is 20°C to 25°C (68°F to 77°F), with occasional excursions allowed between 15°C to 30°C (59°F to 86°F). These tablets are available by prescription only, and the package insert should be read for dosage information. XLcare Pharmaceuticals Inc. manufactured it for Ascent Pharmaceuticals Inc. at Central Islip, NY 11722, and sold under NDC 72865-192-01.*
FDA Label Image

15meq

15meq
This is a description of XLcare potassium citrate extended-release tablets in 15 mEq strength. The tablets are oval-shaped, uncoated, and colored white to tan yellowish. The dosage information can be found in the package insert. The tablets should be stored between 20°C and 25°C (68°F to 77°F), and the manufacturer is Ascent Pharmaceuticals, Inc. The tablets are produced for XLCare Pharmaceuticals, Inc.*
FDA Label Image

5meq

5meq
This is a description of XLcare Potassium Citrate Extended-Release Tablets with a strength of 5 mEq. The tablets are uncoated and round-shaped, with 'T' on one side and '399' on the other. The package insert should be read for dosage information. The tablets should be stored in a tight container at a temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The tablets are manufactured by Ascent Pharmaceuticals, Inc. for XLCare Pharmaceuticals, Inc. and should only be dispensed with a prescription. *
FDA Label Image

Table 1.

Table 1.
Table 1 shows the effect of Potassium Citrate on patients with calcium oxalate nephrolithiasis. The table presents the number of stones formed per year in each group before and during treatment, as well as the percentage of remission and any decrease in the number of stones. Remission is defined as the percentage of patients who remained free of newly-formed stones during treatment.*
FDA Label Image

Structure.

Structure.

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.